Literature DB >> 17503079

Screening and early diagnosis of colorectal cancer in China: a 12 year retrospect (1994-2006).

Shirong Li1, Jiheng Wang, Yuanyuan Lu, Daiming Fan.   

Abstract

Colorectal cancer is one of the most prevalent malignancies in the world. Chinese researchers and clinical doctors had been working hard in the last 12 years, exploring efficient and convenient methods for screening and early diagnosis. The 12 years research works indicated that SFOBT plus colonoscopy was the best detecting protocol for mass screening of colorectal cancer. Serial combined testing for tumor markers plus colonoscopy is the most commonly used strategy for early diagnosis. However, still no optimum method for early diagnosis was generally accepted by most researchers. Due to intrinsic defects of the techniques, several screening and diagnostic methods should be combined to bring each advantage into full play, in order to elevate the diagnostic level of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503079     DOI: 10.1007/s00432-007-0231-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  10 in total

1.  [The relation between DNA replication error and clinicopathological features of colorectal carcinoma].

Authors:  N Xu; H Qiu; Y Ding
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  1998-10

2.  [Laser-induced fluorescence (LIF) spectrum of colorectal cancer in vivo].

Authors:  J Li; S Li; G Gao
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2000-09

3.  [Randomized controlled trial of sequence mass screening program for colorectal cancer].

Authors:  X Liu; S Zheng; K Chen; X Ma; L Zhou; H Yu; K Yao; K Chen; S Cai; S Zhang
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2000-12

4.  [Evaluation of combined test of sequential fecal occult blood and albumin in the screening of colorectal neoplasms].

Authors:  S Li; C Zhang; E Xu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1995-09

5.  [Colorectal exfoliated cell in stool and its nuclear DNA quantitative analysis for diagnosis of colorectal cancer].

Authors:  Ru-ying Fan; Shi-rong Li; Zi-tao Wu; Xia Wu; Zhi-min Chen
Journal:  Ai Zheng       Date:  2002-07

6.  [Clinical significance of galactose oxidase-Schiff reaction in the detection of carcinoma and precancerous lesions of large intestine].

Authors:  J Qin; Q Zhang; X Fang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1997-03

7.  [Study of telomerase activity in colorectal carcinomas].

Authors:  D Zhao; W Zhang; S Jin
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1998-05

8.  Cluster randomization trial of sequence mass screening for colorectal cancer.

Authors:  Shu Zheng; Kun Chen; Xiyong Liu; Xinyuan Ma; Hai Yu; Kang Chen; Kaiyan Yao; Lun Zhou; Linbo Wang; Peiling Qiu; Yongchuan Deng; Suzhan Zhang
Journal:  Dis Colon Rectum       Date:  2003-01       Impact factor: 4.585

9.  [Evaluation of mass screening for colorectal cancer with 'sequential fecal occult blood test' in an asymptomatic population. Multicenter GI Research Group of Beijing Area of PLA].

Authors: 
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1993-05

10.  [A study on the complementary scheme of mass screening for colorectal cancer in an asymptomatic population].

Authors:  D Y Zhou; F C Feng; Y L Zhang
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1994-06
  10 in total
  9 in total

1.  Association between genetic variants in pre-miRNA and colorectal cancer risk in a Chinese population.

Authors:  Meili Lv; Wei Dong; Lijuan Li; Lushun Zhang; Xiaowei Su; Li Wang; Linbo Gao; Lin Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2013-06-02       Impact factor: 4.553

2.  Mitogen/extracellular signal-regulated kinase kinase-5 promoter region polymorphisms affect the risk of sporadic colorectal cancer in a southern Chinese population.

Authors:  Dechang Diao; Lei Wang; Jun-Xiao Zhang; Dianke Chen; Huanliang Liu; Yisheng Wei; Jiachun Lu; Junsheng Peng; Jianping Wang
Journal:  DNA Cell Biol       Date:  2011-08-23       Impact factor: 3.311

3.  Expression of trefoil factors and TWIST1 in colorectal cancer and their correlation with metastatic potential and prognosis.

Authors:  Akram Yusup; Bailikezi Huji; Cheng Fang; Fei Wang; Tuerxunjiang Dadihan; Hai-Jiang Wang; Halmurat Upur
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

4.  Overexpression of Wnt7α protein predicts poor survival in patients with colorectal carcinoma.

Authors:  Yichong Wang; Jiufeng Wei; Shujun Zhang; Guodong Li; Tao Zhang; Xin Yu; Hongsheng Chen; Ming Liu
Journal:  Tumour Biol       Date:  2015-06-09

5.  Proposal of a new classification for stage III colorectal cancer based on the number and ratio of metastatic lymph nodes.

Authors:  Li-Ping Wang; Hong-Yan Wang; Rui Cao; Cong Zhu; Xiong-Zhi Wu
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

6.  Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer.

Authors:  Bang Hu; Donglin Ren; Dan Su; Hongcheng Lin; Zhenyu Xian; Xingyang Wan; Junxiao Zhang; Xinhui Fu; Li Jiang; Dechan Diao; Xinjuan Fan; Lei Wang; Jianping Wang
Journal:  BMC Cancer       Date:  2012-03-30       Impact factor: 4.430

7.  MEK5 overexpression is associated with the occurrence and development of colorectal cancer.

Authors:  Dechang Diao; Lei Wang; Jin Wan; Zhiqiang Chen; Junsheng Peng; Huanliang Liu; Xinlin Chen; Wei Wang; Liaonan Zou
Journal:  BMC Cancer       Date:  2016-05-09       Impact factor: 4.430

8.  Role of serine/threonine kinase 33 methylation in colorectal cancer and its clinical significance.

Authors:  Ming-Di Yin; Si-Ping Ma; Fang Liu; Yu-Ze Chen
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

9.  TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process.

Authors:  Aikeremu Yusufu; Paerhati Shayimu; Rousidan Tuerdi; Cheng Fang; Fei Wang; Haijiang Wang
Journal:  Int J Oncol       Date:  2019-08-05       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.